HOW TO ACCESS AVEGENE SCREENING
Access to genetic screening is regulated differently from country to country. In some countries, medical indication is required, while in others screening services may be accessed directly.
To ensure compliance with applicable national requirements, access to AveGene™ screening is organised through our authorised national distributors and their partners, typically physicians, clinics and healthcare providers. They provide the AveGene™ cfDNA Collection & Transport Kit and ensure that the applicable local requirements for accessing the screening are fulfilled.
Each collection kit contains a unique Activation Code. This code connects the collection kit with the AveGene screening service and is required to activate and purchase your screening online.
Start by selecting your country below and finding your local AveGene distributor or partner.
Lidická 977
Oberer Gansbach 1
Dunajska cesta 199
Recognize it in time!
Select your country and find an authorised AveGene distributor or partner near you.
Your local partner will guide you through the requirements applicable in your country and provide access to the AveGene™ cfDNA Collection & Transport Kit.
Each collection kit contains a unique Activation Code.
Use this code on the AveGene website to activate your kit, select the appropriate screening and complete your purchase.
A valid Activation Code is required to access and purchase AveGene screening.
Have your blood sample collected by a qualified healthcare professional using the AveGene™ cfDNA Collection & Transport Kit.
Use the components provided in the kit to prepare your sample for transport. Then send it by courier to your nearest AveGene collection centre or directly to the AveGene laboratory, following the instructions included with the kit.
When healthy and sick tissue come into contact with the bloodstream, they discharge cellular and genetic material into the circulation. The materials in question are commonly known as “cell-free” DNA (cfDNA) and circulating tumor cells (CTCs). The DNA derived from tumor cells that circulate in the bloodstream is referred to as circulating tumor DNA (ctDNA). The Liquid Biopsy gene panel encompasses a wide range of high-priority genes that are extensively implicated in the advancement of cancer. Multiple particles are discharged into the bloodstream well in advance of the body exhibiting any symptoms. This time gap may be crucial for cancer treatment and that’s where our main motto comes from - “Recognize it in time”.
